Medicare pilot programs aim to reduce prescription drug spend
Seeking Alpha News (Wed, 24-Dec 9:29 AM ET)
Novartis AG (NOVN) Receives a Buy from J.P. Morgan
TipRanks (Tue, 23-Dec 10:15 PM ET)
MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’
TipRanks (Tue, 23-Dec 10:16 AM ET)
Benzinga (Sat, 20-Dec 1:38 AM ET)
Novartis' myasthenia gravis asset iptacopan granted FDA Orphan Drug status
Seeking Alpha News (Fri, 19-Dec 2:57 PM ET)
Market Voices: Trump on Venezuela, CPI data issues, drug pricing deals
Seeking Alpha News (Fri, 19-Dec 1:08 PM ET)
AbbVie, Bristol Myers, Merck among latest to announce U.S. drug pricing deals: Reuters
Seeking Alpha News (Fri, 19-Dec 6:53 AM ET)
Business Wire (Wed, 17-Dec 9:00 AM ET)
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
Globe Newswire (Thu, 20-Nov 8:30 AM ET)
PRNewswire (Tue, 30-Sep 5:23 PM ET)
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of December 24, 2025, NVS stock price declined to $138.88 with 600,139 million shares trading.
NVS has a beta of 0.31, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.06 to the broad based SPY ETF.
NVS has a market cap of $266.48 billion. This is considered a Mega Cap stock.
Last quarter Novartis Ag reported $14 billion in Revenue and $2.25 earnings per share. This beat revenue expectation by $41 million and missed earnings estimates by -$.04.
In the last 3 years, NVS traded as high as $140.18 and as low as $79.98.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, PPH, DFIC, DFAI, DIHP.
NVS has outperformed the market in the last year with a price return of +45.0% while the SPY ETF gained +17.3%. NVS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.1% and +6.0%, respectively, while the SPY returned +4.4% and +1.4%, respectively.
NVS support price is $137.28 and resistance is $140.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.